戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 so known as Arg82 and inositol polyphosphate multikinase).
2  ARG82, which encodes inositol polyphosphate multikinase.
3 r Ipk2 (also known as inositol polyphosphate multikinase), an inositol trisphosphate and tetrakisphos
4 uble forms, the human inositol polyphosphate multikinase, and the two isoforms of IP(3)K found in Dro
5 oups, inositol 3-kinases, inositol phosphate multikinases, and inositol hexakisphosphate kinases.
6                           Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression
7 hosphate 3-kinase and inositol polyphosphate multikinase as key mediators in the production of IP(5).
8                        How Nef assembles the multikinase cascade to trigger the MHC-I down-regulation
9 e to the paranuclear region and assemble the multikinase cascade.
10 us cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-active inhibitor.
11                     Human inositol phosphate multikinase (HsIPMK) critically contributes to intracell
12 iling against 11 homologous kinases revealed multikinase inhibition (CDK2, CDK5, CDK9, and GSK-3alpha
13  or had been treated previously with a VEGFR multikinase inhibitor (cohort 2).
14 FR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity again
15                                              Multikinase inhibitor and immune checkpoint blockade com
16                               Sorafenib is a multikinase inhibitor and the only FDA-approved treatmen
17 pindle cell sarcoma who did not respond to a multikinase inhibitor and therefore had limited treatmen
18                                 Sorafenib, a multikinase inhibitor approved for the treatment of adva
19                                 Sorafenib, a multikinase inhibitor approved for the treatment of RCC,
20 otocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal ce
21                            Cabozantinib is a multikinase inhibitor approved in multiple malignancies.
22  addition, the combination of IACS-10759 and multikinase inhibitor cabozantinib had improved antitumo
23 rum of FDA-approved drugs, we found that the multikinase inhibitor dasatinib potently inhibited the g
24 rug-regulatable system or treatment with the multikinase inhibitor dasatinib resulted in the acquisit
25        These mutations were sensitive to the multikinase inhibitor dasatinib, which antagonizes TNK2
26 y confirmed response reported to date with a multikinase inhibitor in advanced GEP-NETs, with a parti
27                                          The multikinase inhibitor lestaurtinib inhibited PKN1 action
28 previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3
29                                          The multikinase inhibitor META060 has been shown to inhibit
30                                          The multikinase inhibitor midostaurin inhibits KIT D816V, a
31  patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved
32                    GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothel
33                                 Sorafenib, a multikinase inhibitor of cell proliferation and angiogen
34                            Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which
35                              Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and
36              In this study, we show that the multikinase inhibitor PKC412, which is currently in clin
37 tudy assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal
38  SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma su
39 ational phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.
40 down of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced.
41 ition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells.
42                           The effects of the multikinase inhibitor sorafenib (BAY 43-9006), an agent
43                                          The multikinase inhibitor sorafenib (Nexavar, Bayer), used i
44 ve drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to e
45      We examined the interaction between the multikinase inhibitor sorafenib and histone deacetylase
46                      We examined whether the multikinase inhibitor sorafenib and histone deacetylase
47                     Interactions between the multikinase inhibitor sorafenib and the BH3-mimetic obat
48                     Interactions between the multikinase inhibitor sorafenib and tumor necrosis facto
49 te stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in pat
50          We previously demonstrated that the multikinase inhibitor sorafenib induces apoptosis in mel
51                                     Only the multikinase inhibitor sorafenib is available for the man
52 advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic tre
53                             In addition, the multikinase inhibitor sorafenib significantly reduces FB
54                                          The multikinase inhibitor sorafenib yielded similar effects
55 r rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responde
56 antly, we found that the clinically valuable multikinase inhibitor sorafenib, and a natural alkaloid,
57 he molecular mechanism of the oral antitumor multikinase inhibitor sorafenib, we profiled the express
58 the kinase most efficiently inhibited by the multikinase inhibitor sorafenib, which has shown activit
59 patient before and during treatment with the multikinase inhibitor sorafenib.
60 zed with diverse drug classes, including the multikinase inhibitor sorafenib.
61 on increased the therapeutic efficacy of the multikinase inhibitor sorafenib.
62                                 Sorafenib, a multikinase inhibitor targeting cell growth and angiogen
63                      Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR
64 he safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, an
65                         Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and
66                                 Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed an
67  effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculatur
68     Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had
69 n U.S. Food and Drug Administration-approved multikinase inhibitor that also targets Src family, dram
70                               Sorafenib is a multikinase inhibitor that induces apoptosis in human le
71  that mutp53 increases sensitivity to SOR, a multikinase inhibitor that induces endoplasmic reticulum
72      Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating
73  previously unknown drug-like small molecule multikinase inhibitor that regulates splicing of Syngap1
74 sistance could be overcome with ponatinib, a multikinase inhibitor that targets BCR-ABL and FGF recep
75    This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and recept
76                               BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor c
77                         Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK m
78 neoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the serine-threonine
79                         Sorafenib is an oral multikinase inhibitor that was originally developed as a
80                        Sorafenib is an oral, multikinase inhibitor that was recently approved for use
81        Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase a
82                            Cabozantinib is a multikinase inhibitor with activity against RET that pro
83                           Pazopanib, an oral multikinase inhibitor with activity against vascular end
84                               Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferat
85                     Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activit
86                              Crizotinib is a multikinase inhibitor with potent activity against MET(3
87 vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity ag
88 ffects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk ac
89      Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat
90 ION: Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat
91                         Indeed, sorafenib (a multikinase inhibitor) is currently being used in the su
92 evacizumab, atezolizumab alone or sorafenib (multikinase inhibitor).
93                The discovery of sorafenib, a multikinase inhibitor, as a treatment with survival bene
94 rface and sorafenib, a potent antineoplastic multikinase inhibitor, encapsulated in the core.
95                           Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in
96 e of the proteome to the drug Regorafenib, a multikinase inhibitor, in HCT 116 spheroids.
97     Our aim was to ascertain if sorafenib, a multikinase inhibitor, may also inhibit JAK/STAT signali
98                                   Recently a multikinase inhibitor, sorafenib, has shown survival ben
99 h sunitinib (Sutent), an additional approved multikinase inhibitor, suggesting that the primary targe
100 ere sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment.
101 geting nanoparticles (NPs) with sorafenib, a multikinase inhibitor, the NPs could suppress collagen s
102                                 Dasatinib, a multikinase inhibitor, was effective against 50% of DLBC
103 hase I trial combining dasatinib, an SFK and multikinase inhibitor, with erlotinib, an EGFR inhibitor
104 oparticle containing cabozantinib (XL184)--a multikinase inhibitor--encapsulated inside.
105 sses the outcomes of acitretin treatment for multikinase inhibitor-associated hand-foot skin reaction
106 ive iodine who had never been treated with a multikinase inhibitor.
107 ors were also resistant to a VEGFR targeting multikinase inhibitor.
108                               Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, caboz
109 inhibitors (HR = 0.60; 95% CI 0.46-0.79) and multikinase inhibitors (HR = 0.49; 95% CI 0.27-0.89) wer
110                                   The use of multikinase inhibitors (MKI) in oncology, such as sorafe
111 lorectal cancer (mCRC) patients treated with multikinase inhibitors (MKI).
112                                              Multikinase inhibitors (MKIs) showing anti-RET activitie
113 -altered cancers were initially treated with multikinase inhibitors (MKIs).
114                                              Multikinase inhibitors (ponatinib, sunitinib, sorafenib)
115 enib, and regorafenib and resistant to other multikinase inhibitors and chemotherapeutic drugs.
116                               Antiangiogenic multikinase inhibitors and targeted therapies to genetic
117                                              Multikinase inhibitors are effective treatments for thyr
118  hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and ot
119                            Since then, other multikinase inhibitors have been approved.
120 hese cancers, although only early-generation multikinase inhibitors have been granted regulatory appr
121                                              Multikinase inhibitors have shown potential in treating
122 xis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects
123                            The Kit-targeting multikinase inhibitors PKC412 and dasatinib were also fo
124 ma (CRC) metastatic to the liver include the multikinase inhibitors sorafenib and regorafenib.
125 ies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated
126 rapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235,
127                                          The multikinase inhibitors sunitinib, sorafenib, and axitini
128    Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial gr
129          Several new targeted therapies with multikinase inhibitors targeting vascular endothelial gr
130              Despite the approval of several multikinase inhibitors that target SRC and the overwhelm
131 olypharmacological approaches for developing multikinase inhibitors with low toxicity profiles.
132                                              Multikinase inhibitors with RET inhibitor activity, such
133 nter trials evaluating last-line treatments (multikinase inhibitors).
134 a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse
135  from the toxicity profiles of the available multikinase inhibitors.
136 peutic strategy of improving the efficacy of multikinase inhibitors.
137 drives resistance of glioma cells to various multikinase inhibitors.
138 ctivity associated with several FDA-approved multikinase inhibitors.
139 s in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib,
140 nhibitors (TKIs) have significant off-target multikinase inhibitory effects.
141 al structure of the yeast inositol phosphate multikinase Ipk2 in the apoform and in a complex with AD
142  phosphate kinase 2 (Ipk2), also known as IP multikinase IPMK, is an evolutionarily conserved protein
143   We demonstrate that inositol polyphosphate multikinase (IPMK) acts noncatalytically as a transcript
144            RATIONALE: Inositol polyphosphate multikinase (IPMK) and its major product inositol pentak
145 es phosphorylation by inositol polyphosphate multikinase (IPMK) and promotes nuclear actin assembly t
146 tant with the loss of inositol polyphosphate multikinase (IPMK) in murine myocytes, adipocytes, and h
147                       Inositol-polyphosphate multikinase (IPMK) is a central component of the inosito
148                       Inositol polyphosphate multikinase (IPMK) is a kinase linked to several cancers
149  kinase activity of human inositol phosphate multikinase (IPMK) is required for the synthesis of high
150          We show that inositol polyphosphate multikinase (IPMK) physiologically generates PIP(3) as w
151        We report that inositol polyphosphate multikinase (IPMK) regulates glucose signaling to AMPK i
152 ma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-media
153 repair, controlled by inositol polyphosphate multikinase (IPMK), an enzyme catalyzing inositol polyph
154 ficantly increased by inositol polyphosphate multikinase (IPMK), an SRF cofactor.
155 ate kinase (IP6K) and inositol polyphosphate multikinase (IPMK), which synthesize multifunctional ino
156  deletion in the gene inositol polyphosphate multikinase (IPMK), which truncates the protein.
157                           Inositol phosphate multikinase (IPMK, also called Ipk2 and Arg82) accounts
158                       Inositol polyphosphate multikinase is a metformin target that regulates cell mi
159  human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-k
160                          The approval of the multikinase/KIT inhibitor midostaurin has validated the
161 Treatment with midostaurin, an orally active multikinase/KIT inhibitor now approved for advSM in the
162 ently reported phase 2 study, midostaurin, a multikinase/KIT inhibitor, demonstrated an overall respo
163 ch we designate mammalian inositol phosphate multikinase (mIPMK).
164 otransfer within hybrid HKs of the GacS-GacA multikinase network of Pseudomonas brassicacearum.
165  recently emerging theme is the existence of multikinase networks (MKNs) where multiple SKs collabora
166 HKs have recently been shown to form complex multikinase networks (MKNs).
167 odel for studying non-canonical crosstalk in multikinase networks.
168  provide evidence in vivo and in vitro for a multikinase pathway that links extracellular signals to
169 /FU positive regulatory loop nested within a multikinase phosphorylation cascade.
170                    We investigated the novel multikinase PIM/PI3K/mTOR inhibitor, AUM302, versus a co
171 ion of IPMK, encoding inositol polyphosphate multikinase, promotes autophagy and lysosomal function a
172  kinase assay to determine the mechanisms of multikinase substrate phosphorylation such as priming-de
173 gnaling nodes, development of compounds with multikinase targeting was explored.
174 n Trypanosoma brucei: inositol polyphosphate multikinase (TbIPMK), inositol pentakisphosphate 2-kinas
175 sibility and efficacy of adding sorafenib, a multikinase tyrosine kinase inhibitor to standard chemot
176 lts from the COSMIC-312 study evaluating the multikinase vascular endothelial growth factor receptor,
177                       Inositol polyphosphate multikinase was identified as an enzyme that generates a
178  3-kinase activity of inositol polyphosphate multikinase, which is localized to nuclei and unaffected

 
Page Top